Non-coding RNAs function as diagnostic biomarkers and therapeutic targets in pulmonary arterial hypertension

Abstract

Pulmonary arterial hypertension is a disease characterized by complex pathogenesis and high mortality rates following diagnosis. Non-coding RNA plays a pivotal role in the development of pulmonary arterial hypertension, offering promising prospects as a diagnostic and therapeutic target for this condition. The utilization of nucleic acid drugs in disease treatment suggests the feasibility of packaging non-coding RNA into carrier systems and employing them in human pulmonary arterial hypertension (PAH) treatment through appropriate delivery routes. However, currently, no nucleic acid drugs are available for the clinical treatment of PAH. Identifying active regions within non-coding RNA through molecular docking analysis and developing suitable nucleic acid drugs hold great potential for advancing the field of PAH therapeutics.